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Abstract
A fatty acid analogue, 2-(tridec-12-yn-1-ylthio)acetic acid (1-triple TTA), was previously
shown to have hypolipidemic effects in rats by targeting mitochondrial activity predominantly
in liver. This study aimed to determine if 1-triple TTA could influence carbohydrate metabo-
lism. Male Wistar rats were treated for three weeks with oral supplementation of 100 mg/kg
body weight 1-triple TTA. Blood glucose and insulin levels, and liver carbohydrate metabo-
lism gene expression and enzyme activities were determined. In addition, human myotubes
and Huh7 liver cells were treated with 1-triple TTA, and glucose and fatty acid oxidation
were determined. The level of plasma insulin was significantly reduced in 1-triple TTA-
treated rats, resulting in a 32% reduction in the insulin/glucose ratio. The hepatic glucose
and glycogen levels were lowered by 22% and 49%, respectively, compared to control. This
was accompanied by lower hepatic gene expression of phosphenolpyruvate carboxykinase,
the rate-limiting enzyme in gluconeogenesis, and Hnf4A, a regulator of gluconeogenesis.
Gene expression of pyruvate kinase, catalysing the final step of glycolysis, was also
reduced by 1-triple TTA. In addition, pyruvate dehydrogenase activity was reduced, accom-
panied by 10-15-fold increased gene expression of its regulator pyruvate dehydrogenase
kinase 4 compared to control, suggesting reduced entry of pyruvate into the TCA cycle.
Indeed, the NADPH-generating enzyme malic enzyme 1 (ME1) catalysing production of
pyruvate from malate, was increased 13-fold at the gene expression level. Despite the
decreased glycogen level, genes involved in glycogen synthesis were not affected in livers
of 1-triple TTA treated rats. In contrast, the pentose phosphate pathway seemed to be
increased as the hepatic gene expression of glucose-6-phosphate dehydrogenase (G6PD)
was higher in 1-triple TTA treated rats compared to controls. In human Huh7 liver cells, but
not in myotubes, 1-triple-TTA reduced glucose oxidation and induced fatty acid oxidation, in
line with previous observations of increased hepatic mitochondrial palmitoyl-CoA oxidation
in rats. Importantly, this work recognizes the liver as an important organ in glucose
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homeostasis. The mitochondrially targeted fatty acid analogue 1-triple TTA seemed to lower
hepatic glucose and glycogen levels by inhibition of gluconeogenesis. This was also linked
to a reduction in glucose oxidation accompanied by reduced PHD activity and stimulation of
ME1 and G6PD, favouring a shift from glucose- to fatty acid oxidation. The reduced plasma
insulin/glucose ratio indicate that 1-triple TTA may improve glucose tolerance in rats.
Introduction
The insulin resistance syndrome or the metabolic syndrome is a collection of risk factors char-
acterized by elevated plasma triacylglycerol (TAG) and low-high-density lipoprotein-choles-
terol (HDL-cholesterol), abdominal obesity, hypertension and elevated blood glucose. The
metabolic syndrome is strongly linked to hyperinsulinemia, insulin resistance, glucose intoler-
ance and/or type 2 diabetes mellitus, as well as dyslipidemia.
Given that mitochondrial function and mitochondrial fatty acid oxidation capacity seem to
regulate TAG levels both in liver and plasma, we have synthesized 2-(tridec-12 -yn-1-ylthio)
acetic acid (1-triple TTA) which target the mitochondria (1). Notably,1-triple TTA has the
length as a palmitic acid, in which the beta-carbon is substituted with a sulphur atom. In addi-
tion, it has a triple bond at the omega -end making it resistant to both beta-oxidation and
omega-degradation. We have previously shown that liver-specific mitochondrial proliferation
induced by (1-triple TTA)-treatment strongly reduces liver and plasma TAG levels [1,2]. The
1-triple TTA-mediated clearance of plasma TAG involves increased mitochondrial fatty acid
oxidation, and may also result from lowered apolipoprotein C-III levels with subsequent
increased lipoprotein protein lipase activity, and a possible hepatic reuptake of very low-den-
sity lipoprotein, facilitating drainage of fatty acids to the liver for β-oxidation and production
of ketone bodies as extrahepatic fuel [2]. Both lipid- and carbohydrate metabolism are regu-
lated by processes taking place in the liver. Thus, the ability of 1-triple TTA to regulate hepatic
energy status and mitochondrial function prompted us to investigate whether 1-triple TTA
could modulate glucose homeostasis.
Glucose homeostasis is physiologically maintained by the balance between glucose produc-
tion by the liver and glucose utilization by peripheral tissues [3]. Moreover, liver is important
to regulate plasma glucose levels during fasting and diabetic conditions both by degradation of
its glycogen stores and through increased gluconeogenesis, and notably, increased fatty acid
oxidation in the liver is generally thought to stimulate gluconeogenesis [4]. Phosphoenolpyr-
uvate carboxykinase (PEPCK) and glucose-6-phosphatase catalyze the rate-limiting steps of
gluconeogenesis (Fig 1) and the decarboxylation of oxaloacetate into phosphoenolpyruvate is
obligate for mitochondrial-derived gluconeogenesis. Generally, this reaction has been attrib-
uted to the cytosolic isoform of PEPCK (PEPCK-C) although the mitochondrial isoform
(PEPCK-M) could be involved in both normal and diabetic metabolism [5].
Gluconeogenesis can be considered the reversal of glycolysis [6] where glucose is converted
to pyruvate (Fig 1). The last step in glycolysis is the conversion of phosphoenolpyruvate to
pyruvate catalyzed by the rate-limiting enzyme pyruvate kinase. When glucose is abundant,
i.e. during the fed state, glycolysis is active; glucose is converted to pyruvate in order to gener-
ate ATP and provide building blocks for cellular components. The pyruvate dehydrogenase
(PDH) complex is a multi-enzyme complex regulating the conversion pyruvate to acetyl-CoA
in the mitochondrial matrix. Reversely, the complex is inactivated during fasted states to
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conserve glucose and therefore shifts the cell´s energy supply from glucose to fatty acid oxida-
tion [7].
The hexosamine biosynthesis pathway is a relatively minor branch of glycolysis. It utilizes
fructose 6-phosphate as substrate, and encompasses approximately 3% of total glucose used.
Elevated o-linked N-acetylglucosamine (OGT) levels implies increased hexosamine biosynthe-
sis pathway-flux [8]. Several reports have proposed that flux through the hexosamine synthesis
pathway may function as a cellular nutrient sensor and play a role in the development of insu-
lin resistance and vascular complications of diabetes [8,9].
The pentose phosphate pathway is an anabolic pathway parallel to glycolysis, which gener-
ates pentoses and ribose-5 phosphate from glucose. The pathway is important for the synthesis
of nucleotides and aromatic amino acids. Glucose 6-phosphate dehydrogenase is the rate limit-
ing enzyme of this pathway, and the production of NADPH during this step in the oxidative
phase of the pathway can be used in i.e. fatty acid synthesis [10].
Fig 1. Glucose metabolism pathways in the liver. Abbreviations: glucose transporter 2 (GLUT2/Slc2a2); glucokinase
phosphofructokinase (Pfkl); pyruvate kinase L/R (Pklr); pyruvate dehydrogenase kinase, isoenzyme 2 (Pdk2); pyruvate
dehydrogenase kinase, isoenzyme 4 (Pdk4); pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1); pyruvate carboxylase
(Pc); glucose-6 phosphatase (G6pc); glycogen synthetase 2 (Gys2); Gys3a; hepatic glycogen synthetase 3 beta (Gsk3b);
glucose-6-phosphate dehydrogenase (G6pd); malic enzyme 1 (Me1); o-linked N-acetylglucosamine transferase (OGT).
https://doi.org/10.1371/journal.pone.0222558.g001
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While TAG stored in adipose tissue is considered the principle energy reserve in
mammals, in addition, glucose is stored as glycogen in liver and skeletal muscle, for rapid
mobilization during times of energy deficit. Moreover, muscle and liver glycogen deposition is
decreased during insulin resistance and type 2 diabetes mellitus [11,12]. Elevated fasting
plasma TAG is associated with dysregulation of glucose and as stimulated mitochondrial fatty
acid oxidation is known to reduce plasma TAG (triacylglycerol), drugs that target mitochon-
drial function can potentially also improve glucose homeostasis and prevent type 2 diabetes
[13–15].
In this study, we aimed to test how 1-triple TTA regulates plasma and hepatic glucose
homeostasis, by studying key genes in hepatic glycolysis, gluconeogenesis, glycogen synthesis,
the hexosamine biosynthesis pathway and the pentose phosphate pathway in rats and in vitro
in human cell lines and primary cells.
Materials and methods
Animal study
The animal study was conducted according to the Guidelines for the Care and Use of Experi-
mental Animals, in accordance with the Norwegian legislation and regulations governing
experiments using live animals, and approved by the Norwegian State Board of Biological
Experiments with Living Animals (Permit number 2015–7367). Male Wistar rats, Rattus Nor-
vegicus, 5 weeks old, were purchased from Taconic (Ejby, Denmark). Upon arrival the rats
were randomized using Research Randomizer [16], labeled and placed in open cages, four in
each cage, where they were allowed to acclimatize to their surroundings for one week. During
the acclimatization and experiment period, the rats had unrestricted access to chow and tap
water and were kept in a 12 h light/dark cycle at a constant temperature (22 ± 2˚C) with a rela-
tive humidity of 55% (± 5%). Upon start of the experiment, the rats were block randomized to
their respective interventions. During the three weeks long experiment, there were two rats in
each cage separated with a divider that let them have sniffing contact. All rats were given chow
throughout the experiment. In addition, group 1, control (n = 8) received 0.5 ml 0.5% methyl-
cellulose from the Hospital Pharmacy (Bergen, Norway) daily and group 2 (n = 6) received
100 mg/kg body weight 1-triple TTA (C15H26O2S, obtained from Synthetica AS, Oslo, Nor-
way) dissolved in 0.5 ml 0.5% methylcellulose daily. Methylcellulose was given orally by gavage
by a technician blinded to the experimental setup. All animals were weighed daily and feed
intake was determined weekly.
At sacrifice, rats, equally divided between groups throughout the day, were anaesthetized by
inhalation of 2–5% isoflurane (Schering-Plough, Kent, UK), the abdomen opened along the
midline, and exsanguination was performed using cardiac puncture. EDTA-blood was col-
lected and immediately chilled on ice. The samples were centrifuged and plasma was stored at
—80˚C prior to analysis. Liver was collected and weighed and a fresh sample from each liver
was used for β-oxidation analysis. The remaining part of the liver was immediately snap-frozen
in liquid nitrogen and stored at—80˚C until further analysis.
Plasma glucose and insulin
Glucose was measured enzymatically in EDTA-plasma on a Hitachi 917 system (Roche
Diagnostics GmbH, Mannheim, Germany) using the GLUC2 kit from Roche Diagnostics.
Insulin was measured using the Rat/Mouse insulin ELISA kit from Merck (Darmstadt,
Germany).
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Pyruvate dehydrogenase activity in liver
Using TissueLyzer II (Qiagen, Hilden, Germany), approximately 100 mg frozen liver sample
from each animal was homogenized in 500 μl PDH assay buffer from the pyruvate dehydroge-
nase activity assay kit (MAK 183, Sigma-Aldrich, St. Louis, MO, USA). Homogenates were
centrifuged for 5 min at 10.000 x g at 4˚C, the supernatant was removed and added 2 volumes
of 4 M ammonium sulphate, and precipitation allowed to occur for 20 min on ice before re-
centrifugation as above. The pellet was resuspended to the original volume using PDH assay
buffer, and 2 μl per sample was used to analyse PDH activity according to the supplier’s man-
ual. Protein was measured using the DC Protein Assay (Bio-Rad Laboratories, Hercules, CA,
USA), and activity per mg protein was calculated.
Hepatic glycogen, glucose, fructose 6-phosphate and NADPH
Using TissueLyzer II (Qiagen, Hilden, Germany), approximately 50 mg frozen liver sample
from each animal was homogenized in 500 μl PBS (10%) at 2 min 25 Hz x 2, before sonication
in a sonicator water bath for 30 sec with 15 sec pause x 3. After centrifugation at full speed for
5 min at 4˚C, the supernatant was frozen in aliquots at -20˚C. A 50 μl sample volume was used
in the NADPH assay kit, and 10 ul of a 1:4 diluted homogenate was used in the fructose
6-phosphate assay kit according to the supplier’s manuals (both from Abcam, Cambridge,
Great Britain). For measurement of glycogen and glucose, 10% homogenates in water were
prepared using TissueLyzer as above, followed by 10 min at 100˚C. Homogenates were centri-
fuged at 17.000 x g for 10 minutes at 4˚Ca nd stored at -20˚C. For the Abcam Glycogen Assay
Kit, homogenates were diluted 1:100 and 30 μl sample volume was used. For the Abcam Glu-
cose Assay Kit, homogenates were diluted 1:30 and 25 μl sample volume was used. For all
homogenates, protein was measured using the DC Protein Assay (Bio-Rad Laboratories).
Hepatic palmitoyl-CoA oxidation. 1 g fresh liver sample was chilled on ice and homoge-
nized in 4 ml ice-cold sucrose medium (0.25 M sucrose, 10 mM HEPES, and 1 mM Na4EDTA,
adjusted to a pH of 7.4 with KOH/HCl) as previously described [17]. The homogenates were
centrifuged at 1030 RCF for 10 min at 4˚C and the post-nuclear fraction was removed and
used for further analysis. Palmitoyl-CoA oxidation was measured immediately in the post-
nuclear fraction from fresh liver as acid-soluble products, as described [18]. The amount of
protein was measured by the DC Protein Assay kit (Bio-Rad Laboratories).
Hepatic gene expression analysis
Tissue samples (20 mg frozen liver) were homogenized in Rneasy Lysis Buffer from Qiagen
(Cat.: 79216, Hilden, Germany) with 1% β-mercaptoethanol using Tissuelyser II (Qiagen) for
2x 2 min at 25 Hz, and total cellular RNA was further purified using the RNeasy mini kit (Qia-
gen, Hilden, Germany) including DNase digestion. 500 ng RNA was reverse transcribed using
High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Waltham, Massachu-
setts, USA). qPCR was performed on Sarstedt 384-well Multiply-PCR plates (Sarstedt Inc.,
Newton, NC, USA) using ABI Prism 7900HT Sequence detection system from Applied Biosys-
tems with the software SDS 2.3. Together with 2x Taqman buffer from Applied Biosystems,
the following probes and primers from Applied Biosystems were used to detect mRNA levels
of interests: Insulin receptor (Insr); glucose transporter 2 (GLUT2/Slc2a2); glucokinase phos-
phofructokinase (Pfkl); pyruvate kinase L/R (Pklr); pyruvate dehydrogenase kinase, isoenzyme
2 (Pdk2); pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4); pyruvate dehydrogenase kinase,
isoenzyme 1 (Pdk1); phosphoenolpyruvate carboxykinase, cytosolic (PEPCK-C/Pck1); phos-
phoenolpyruvate carboxykinase-mitochondrial (PEPCK-M/Pck2); pyruvate carboxylase (Pc);
hepatocyte nuclear factor 4a (Hnf4a); glucose-6 phosphatase (G6pc); glycogen synthetase 2
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(Gys2); Gys3a; hepatic glycogen synthetase 3 beta (Gsk3b); glucose 6-phosphate dehydrogenase
(G6pd); malic enzyme 1 (Me1); sterol regulatory element-binding protein 1 (Srebp1); stearoyl-
CoA desaturase (Scd-1); MLC interacting protein like/ChREBP (Mlxipl); o-linked N-acetylglu-
cosamine transferase (Ogt). Each probe was run with standard curve using either a representa-
tive cDNA sample or cDNA from universal rat reference RNA (URRR, Agilent). Expression
levels were normalized to the average of the reference gene large ribosomal protein P0 (36b4,
acc.no. M17885), and values relative to control are shown.
Culturing of human myotubes
Multinucleated human myotubes were established by activation and proliferation of satellite
cells isolated from a small biopsy (100–200 mg) of musculus vastus lateralis from four healthy
men (age 21–29 years, weight 67–83 kg). The biopsies were obtained after informed written
consent and approval by the Regional Committee for Medical and Health Research Ethics
South East, Oslo, Norway (reference number: 2011/2207). Isolation of satellite cells was based
on the method of Henry et al. [19], modified according to Gaster et al. [20,21], For prolifera-
tion of myoblasts DMEM-Glutamax™ (5.5 mM glucose) medium supplemented with 2% FBS
and 2% Ultroser G was used. At approximately 80% confluence the culture medium was
changed to DMEM-Glutamax™ (5.5 mM glucose) supplemented with 2% FBS and 25 pM insu-
lin to initiate differentiation into multinucleated myotubes. The cells were differentiated for
seven days. 1-triple TTA or vehicle (DMSO) were added 96 h before harvesting.
Culturing of Huh7 cells
Human hepatoma Huh7 cells, purchased from ATCC (LGC Standards, Middlesex, UK), were
grown in DMEM-Glutamax™ (5.5 mM glucose) medium supplemented with 10% FBS. 1-triple
TTA or vehicle (DMSO) were added 48 h before harvesting.
RNA isolation and analysis of gene expression by qPCR in Huh7 cells
Total RNA was isolated from cells using the RNeasy Mini Kit according to the supplier’s proto-
col. RNA was reversely transcribed with a High-Capacity cDNA Reverse Transcription Kit
and TaqMan Reverse Transcription Reagents using a PerkinElmer 2720 Thermal Cycler (25˚C
for 10 min, 37˚C for 80 min, 85˚C for 5 min). Primers were designed using Primer Express1
(Applied Biosystems). qPCR was performed using a StepOnePlus Real-Time PCR system
(Applied Biosystems). Target genes were quantified in duplicates carried out in a 25 μl reaction
volume according to the supplier´s protocol. All assays were run for 44 cycles (95˚C for 15 s
followed by 60˚C for 60 s). Expression levels were normalized to the average of the housekeep-
ing gene large ribosomal protein P0 (36B4, acc.no. M17885). The following primers were used:
36B4; CD36 molecule (CD36, acc.no. L06850); cytochrome c-1 (CycC, acc.no. NM001916);
pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4, acc.no. BC040239); pyruvate kinase L/R
(PKLR, acc.no NM000298); uncoupling protein 2 (UCP2, acc.no AF019409.1); uncoupling
protein 3 (UCP3, acc.no. AF050113).
Oxidation and uptake of glucose and fatty acids in Huh7 cells and cultured
human myotubes
Cells were cultured on 96-well CellBIND1microplates. [1-14C]oleic acid (18.5 kBq/ml),
100 μM, or D-[14C(U)]glucose (21.46 kBq/ml), 200 μM, were given during 4 h CO2 trapping as
previously described [22]. In brief, a 96-well UniFilter1-96 GF/B microplate was mounted on
top of the CellBIND1 culture plate and CO2 production was measured in DPBS medium with
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10 mM HEPES and 1 mM L-carnitine adjusted to pH 7.2–7.3. CO2 production and cell-associ-
ated (CA) radioactivity were assessed using a 2450 MicroBeta2 scintillation counter (PerkinEl-
mer). The sum of 14CO2 and CA radioactivity was taken as a measurement of total cellular
uptake of substrate. Protein content in each well was measured according to Bradford [23].
Glycogen synthesis in Huh7 cells
Huh7 cells grown in 12-well plates were incubated in DMEM containing 5.5 mM glucose sup-
plemented with D-[14C(U)]-glucose (37 kBq/ml) as described [24] for 4 h. Briefly, after wash-
ing cells twice with ice-cold phosphate buffered saline (PBS), cells were exposed to 1 M
potassium hydroxide (KOH) for solubilization. Afterwards, samples were incubated with a
final concentration of 3 M KOH and 20 mg/ml glycogen and heated at 80˚C for 20 min. Glyco-
gen precipitates were received by adding ice-cold absolute ethanol, washed once with 70% eth-
anol and dissolved in 500 μl distilled water. Incorporated D-[14C(U)]-glucose was assessed by
liquid scintillation counting. Protein content was measured according to Bradford [23].
Glucose output in Huh7 cells
Huh7 cells cultured in 12-well plates were incubated in DMEM containing 5.5 mM glucose
supplemented with D-[14(U)]-glucose (37 kBq/ml) for 4 h. After washing twice with PBS, the
cells were incubated in DPBS medium with 10 mM HEPES without glucose. An aliquot of the
medium was withdrawn after 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5 and 5 h and the radioactivity assessed
by liquid scintillation counting. Protein content in each well was measured according to Brad-
ford [23].
Statistical analysis
Statistical difference was analyzed using Student’s t-test on the primary outcomes; glucose and
insulin levels, and the secondary outcome;s hepatic gene expression and enzyme activities. P-
values< 0.05 were considered significant. The results are shown as means ± standard devia-
tion (SD) of 5–8 rats per group, or means ± SEM for cell culture analyses. Pearson’s correlation
coefficients were used when comparing two independent variables. The statistics was per-
formed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp. Armonk, USA) and
graphs were designed with GraphPad Prism for Windows, Version 6.00 (GraphPad Software,
La Jolla, CA, USA).
Results
1-triple TTA affected hepatic mitochondrial function and decreased
insulin in plasma
Three weeks of 1-triple TTA treatment in rats increased hepatic fatty acid oxidation (Fig 2A),
but did not affect weight gain or food intake. In Huh7 liver cells, the 1-triple TTA-induced
increase in oxidation of oleic acid (Fig 2B) was associated with unchanged fatty acid uptake
(Fig 2C), and gene expression of CycC, CD36, UCP2 and UCP3 remained unaltered (Fig 2D).
No increased fatty acid oxidation was found in cultured human skeletal muscle cells (Fig 2E),
suggesting that the effect of 1-triple TTA is cell type specific. This is in line with findings dem-
onstrating no change in energy state in skeletal muscle from 1-triple TTA-treated rats, whereas
in liver a lowered energy state was found reflected by an increased AMP/ATP-ratio [2].
The liver is important for the regulation of the plasma glucose level, and thus 1-triple TTA
as a liver targeted compound could potentially influence plasma glucose and insulin. Treat-
ment of rats with 1-triple TTA for 21 days tended to lower the plasma glucose level compared
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Fig 2. Effects 1-triple TTA (1-tTTA) on fatty acid metabolism and plasma insulin and glucose levels both in vivo
and in vitro. (a) Rats were treated with vehicle (control) or 100 mg/kg body weight 1-tTTA for 3 weeks and palmitoyl-
CoA oxidation in liver was measured (n = 5–8). (b) Oleic acid oxidation and (c) oleic acid uptake, measured as
described in Materials and Methods, in human Huh7 liver cells treated with vehicle (control) or 1-triple-TTA for 48 h
(n = 6–8). (d) Gene expression of cytochrome c-1 (CycC), CD36 molecule (CD36), uncoupling protein (UCP)2 and
UCP3 in Huh7 cells treated with 10 μM 1-tTTA for 48 h (n = 6–8). (e) Oleic acid oxidation and uptake in human
myotubes treated with 10 μM 1-tTTA for 96 h (n = 4). (f) Plasma glucose, (g) insulin, and (h) insulin/glucose ratio in
rats treated with vehicle (control) or 1-tTTA for 3 weeks (n = 5–8). Values shown are means with standard deviation.
Statistically significant differences between means were determined using Students t-test, �p< 0.05 vs. control.
https://doi.org/10.1371/journal.pone.0222558.g002
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to control (Fig 2F, p = 0.076). The plasma insulin level was significantly reduced in the 1-triple
TTA treated group (Fig 2G). The lower insulin/glucose ratio in the 1-triple TTA treated rats is
indicative of insulin sensitization after 1-triple TTA-treatment (Fig 2H).
1-triple-TTA changed hepatic glycolysis, gluconeogenesis and glycogen
synthesis
1-triple TTA could potentially influence the homeostatic control of blood glucose and insulin
action through its hepatic effects. This prompted us to investigate key genes in glycolysis, glu-
coneogenesis and glycogen synthesis in liver. Three weeks of 1-triple TTA-treatment in rats
did not alter hepatic gene expression of insulin receptor (Insr), however, the mRNA levels of
glucose transporter 2 (Slc2a2), was significantly decreased in liver by 1-triple TTA (Fig 3A and
3B). While hepatic gene expression of glucokinase and phosphofructokinase (Pfkl) were
unchanged (Fig 3C and 3D), pyruvate kinase (Pklr) and the activity of PDH were significantly
decreased by 1-triple TTA (Fig 3E and 3F). PDH is a mitochondrial multiplex enzyme and one
of the major regulators of carbohydrate fuel homeostasis in mammals. It is regulated by a
phosphorylation/dephosphorylation cycle, and in line with the decreased PDH activity (Fig
3F), gene expression of one of its major regulators, Pdk4, was markedly increased (10-15-fold)
by 1-triple TTA (Fig 3H). In contrast, the hepatic gene expression of other kinases involved in
PDH inactivation, Pdk1 and Pdk2, remained unaltered after 1-triple TTA-administration (Fig
3G and 3I).
Noteworthy, in human Huh7 liver cells, the highest concentration of 1-triple TTA
(100 μM) reduced glucose oxidation and glucose uptake (Fig 4A and 4B). These findings were
associated with a significantly increased gene expression of Pdk4 whereas the pyruvate kinase
(Pklr) expression remained unchanged (Fig 4C).
We next investigated whether 1-triple TTA caused changes in mRNA expression of key
genes in gluconeogenesis and glycogen synthesis and -formation in rats. 1-triple TTA signifi-
cantly reduced gene expression of Pck1 (encoding PEPCK-C), whereas the mRNA level of
Pck2 (PEPCK-M) remained unaltered (Fig 5A and 5B). The mRNA level of pyruvate carboxyl-
ase (PC), the first regulatory enzyme of gluconeogenesis catalyzing the reaction of pyruvate to
oxaloacetate, remained unchanged after 1-triple TTA treatment (Fig 5C). However, the gene
expression of hepatocyte nuclear factor 4a (Hnf4a), shown to regulate expression of PC [25],
was significantly reduced by 1-triple TTA (Fig 5D). Moreover, the gene expression of glucose-
6 phosphatase (G6pc) remained unaltered in the 1-triple TTA treated animal group (Fig 5E).
Decreased expression of genes involved in gluconeogenesis seemed to be associated with
decreased levels of liver glycogen and glucose (Fig 5F and 5G). However, 1-triple TTA did not
change the gene expression of glycogen synthetase 2 (Gys2), glycogen synthetase kinase 3
alpha (Gsk3a) or the mRNA level of hepatic glycogen synthetase 3 beta (Gsk3b) (Fig 5H–5J).
Moreover, glucose release and glycogen synthesis in Huh7 cells were insignificantly decreased
by 4 days of 1-triple TTA treatment (Fig 6).
1-triple TTA changes the pentose phosphate pathway but not the
hexosamine biosynthesis pathway
The pentose phosphate pathway is a metabolic pathway parallel to glycolysis, with glucose
6-phosphate dehydrogenase as the rate-limiting enzyme. Noteworthy, in rats treated with
1-triple TTA, increased gene expression of glucose 6-phosphate dehydrogenase (Fig 7A) was
associated with an insignificant decrease in the hepatic level of NADPH (Fig 7B). Moreover,
the mRNA level of malic enzyme (Me1), which generates NADPH for i.e. fatty acid biosynthe-
sis, was significantly increased (10-15-fold) by 1-triple TTA in rats (Fig 7C). The sterol
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Fig 3. Hepatic mRNA levels and activity of enzymes involved in glycolysis after 3 weeks treatment with vehicle
(control) or 1-triple TTA (1-tTTA) in rats. (a) Insulin receptor mRNA level, (b) Slc2a2 mRNA level, (c) glucokinase
mRNA level, (d) phosphofructokinase (Pfkl) mRNA level, (e) pyruvate kinase mRNA level, (f) pyruvate dehydrogenase
(PDH) complex activity, (g) pyruvate dehydrogenase kinase, isoenzyme 2 (Pdk2) mRNA level, (h) pyruvate
dehydrogenase kinase, isoenzyme 4 (Pdk4) mRNA level, (i) pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1)
mRNA level. Gene expression levels were normalized to the house keeping gene Rplp0 and relative values are given. All
values shown are means with standard deviation (n = 6–8). Statistically significant differences between means were
determined using Students t-test, �p< 0.05 vs. control.
https://doi.org/10.1371/journal.pone.0222558.g003
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regulatory element-binding protein 1 (SREBP-1) represents a master regulator of biosynthesis
of lipids from i.e. glucose [26]. 1-triple TTA increased gene expression of Srebf1, whereas gene
expression of stearoyl-CoA desaturase (Scd-1) remained unchanged (Fig 7D and 7E). In the
liver, the carbohydrate-responsive element-binding protein (ChREBP) mediates activation of
several regulatory enzymes of glycolysis and lipogenesis [27]. The hepatic gene expression of
ChREBP (Mlxipl) tended to increase by 1-triple TTA, but this was not statistically significant
(Fig 7F).
Fructose 6-phosphate (F6P), which is the entry substrate for the hexosamine biosynthesis
pathway, remained unchanged after 1-triple TTA-administration in rats (Fig 7G). Similarly,
the gene expression of o-linked N-acetylglucosamine transferase (Ogt), important in regula-
tion the flux in the hexosamine biosynthesis pathway, was unaffected by 1-triple TTA-admin-
istration (Fig 7H).
Discussion
This work demonstrates that the hypolipidemic mitochondria-targeted compound 1-triple
TTA significantly reduced liver glycogen and glucose content and also tended to reduce
plasma glucose (p< 0.076) levels in rats. Indeed, the plasma insulin level was significantly
reduced accompanied by a reduced plasma insulin/glucose ratio. This was linked to suppres-
sion of gluconeogenesis, most likely combined with inhibition of glucose utilization through
reduced activity of PDH and increased expression of PDK4. These findings were supported by
observations of lowered glucose oxidation in human Huh7 liver cells treated with 1-triple
TTA, and of increased liver-specific fatty acid oxidation in rats. Altogether, this indicates that
1-triple TTA has potential as an antidiabetic drug.
The liver is one of the main organs for glucose storage and it plays a crucial role in blood
glucose regulation and indeed hepatic glucose production has been shown to be important in
the development of hyperglycemia in diabetes mellitus patients [28]. Moreover, it has been
reported that increased gluconeogenesis in the liver results in glucose intolerance in animals
models [29], and in most animal models of diabetes expression levels of PEPCK are elevated
[30]. PEPCK, which is one of the rate-limiting enzymes of gluconeogenesis, is regulated by
Fig 4. Effects 1-triple TTA (1-tTTA) on glucose metabolism and gene expression in Huh7 cells. Huh7 cells were treated with vehicle
(control) or 1-tTTA for 48 h. (a) Glucose oxidation. (b) glucose uptake. (c) mRNA expression of pyruvate dehydrogenase kinase, isoenzyme 4
(PDK4) and pyruvate kinase L/R (PKLR) after treatment with 10 μM 1-tTTA. Gene expression levels were normalized to the house keeping gene
RPLP0 and relative values are given. A, B: n = 5, C: n = 4–8. Statistically significant differences between means were determined using Students
t-test, �p< 0.05 vs. control.
https://doi.org/10.1371/journal.pone.0222558.g004
A fatty acid analogue influences hepatic glucose metabolism in male Wistar rats
PLOS ONE | https://doi.org/10.1371/journal.pone.0222558 September 24, 2019 11 / 17
different hormones at the transcription level. Accordingly, suppression of PEPCK gene
expression (Pck1 and Pck2) is a potential target for mitochondrial proliferating antidiabetic
drugs. Administration of 1-triple TTA strongly decreased gene expression of Pck1, whereas
the mRNA level of Pck2 remained unaltered compared to control animals. A role for
Fig 5. Hepatic glucose and glycogen levels, and mRNA levels of enzymes involved in gluconeogenesis and
glycogen synthesis after 3 weeks treatment with vehicle (control) or 1-triple TTA (1-tTTA) in rats. (a)
Phosphoenolpyruvate carboxykinase, cytosolic (PEPCK-C/Pck1) mRNA level, (b) phosphoenolpyruvate
carboxykinase-mitochondrial (PEPCK-M/Pck2) mRNA level, (c) pyruvate carboxylase (Pc) mRNA level, (d)
hepatocyte nuclear factor 4a (Hnf4a) mRNA level, (e) glucose-6 phosphatase (G6pc) mRNA level, (f) the hepatic
glucose level, (g) the hepatic glycogen level, (h) glycogen synthetase 2 (Gys2) mRNA level, (i) Gys3a mRNA level, (j)
glycogen synthetase 3 beta (Gsk3b) mRNA level. Gene expression levels were normalized to the house keeping gene
RPLP0 and relative values are given. All values shown are means with standard deviation (n = 6–8). Statistically
significant differences between means were determined using Students t-test, �p< 0.05 vs. control.
https://doi.org/10.1371/journal.pone.0222558.g005
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mitochondrial PEPCK in the regulation of hepatic gluconeogenesis has been suggested [5,31].
However, our results indicate that the lowering of the insulin/glucose ratio observed with 1-tri-
ple TTA is mediated through the cytosolic isoform of PEPCK (PEPCK-C) and not the mito-
chondrial isoform (PEPCK-M).
The next question raised is how 1-triple TTA suppressed Pck1 gene expression. In the pres-
ent study 1-triple TTA had no effect on the mRNA level of glucokinase (Fig 3C) and we have
previously reported that 1-triple TTA did not change AMPK phosphorylation [2]. Thus, the
effect of 1-triple TTA on PEPCK–C gene expression seemed not to be mediated through the
AMPK pathway. Interestingly, HNF4 is reported to be a regulator of both PEPCK and pyru-
vate kinase. In the present study in rats, gene expression of Hnf4a was decreased in parallel
with a decreased mRNA level of Pck1. Thus, decreased expression of Hnf4a mRNA would be
responsible for a lower amount of Pepck and Pck1 mRNA. HNF4 promotes Chrebp gene tran-
scription in response to glucose and the target genes of CHREBP are involved in glycolysis,
gluconeogenesis and lipogenesis. Moreover, glucose and insulin coordinately regulate de novo
lipogenesis from glucose in the liver and insulin activates several transcription factors includ-
ing SREBP-1C. Interestingly, 1-triple TTA increased the gene expression of Srebf1 and tended
to increase the mRNA levels of Chrebp as well as Scd-1, encoding a desaturase catalyzing an
important step in lipogenesis.
PDH, located in the mitochondrial matrix, is the first component enzyme of the pyruvate
dehydrogenase complex, which contributes to transforming pyruvate into acetyl-CoA, which
can be used in the citric acid cycle and subsequent cellular respiration. Thus, PDH contributes
to linking the glycolysis metabolic pathway to the citric acid cycle and the release of energy via
Fig 6. Effects 1-triple TTA (1-tTTA) on glucose output (a) and glycogen synthesis (b) in Huh7 cells. Huh7 cells were treated with vehicle
(control) or 10 μM 1-tTTA for 48 h. Glucose output and glycogen synthesis were measured as described in Materials and Methods. All values
shown are means with standard deviation (n = 3).
https://doi.org/10.1371/journal.pone.0222558.g006
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NADH. PDK4 is also located in the mitochondrial matrix and inhibits the pyruvate dehydro-
genase complex by phosphorylating one of its subunits, thereby contributing to the regulation
of glucose homeostasis. This is particularly important during starvation, where inhibition of
PDH blocks the oxidation of glucose as well as gluconeogenetic substrates originating from
muscle breakdown [32]. Thus, glucose is spared for use in the brain, and muscle breakdown is
prevented during prolonged starvation. Interestingly, 1-triple TTA dramatically decreased
Fig 7. Hepatic NADPH level and expression of genes involved in the pentose phosphate pathway and the
hexosamine pathway after 3 weeks treatment with vehicle (control) or 1-triple TTA (1-tTTA) in rats. (a) glucose-
6-phosphate dehydrogenase (G6pd) mRNA level, (b) NADPH level, (c) malic enzyme (Me) mRNA level, (d) sterol
regulatory element-binding protein 1 (Srebp1) mRNA level, (e) stearoyl-CoA desaturase (Scd-1) mRNA level, (f)
ChREBP (Mlxipl) mRNA level, (g) fructose-6-phosphate (F6P) level, (h) o-linked N-acetylglucosamine transferase
(Ogt) mRNA level. Gene expression levels were normalized to the house keeping gene RPLP0 and relative values are
given. All values shown are means with standard deviation (n = 6–8). Statistically significant differences between
means were determined using Student’s t-test, �p< 0.05 vs. control.
https://doi.org/10.1371/journal.pone.0222558.g007
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PDH activity accompanied by a strong increase in gene expression of Pdk4. This is in line with
reduced PDH activity and reduced oxidation of glucose. Noteworthy, the mRNA levels of
Pdk1 and Pdk2 were not affected by 1-triple TTA, indicating that they are less important dur-
ing inhibition of PDH activity by 1-triple TTA. Induced expression of Pdk4 in Huh7 cells sup-
port a specific effect of 1-triple TTA on PDH activity.
The hexosamine biosynthesis pathway is a relative minor branch of glycolysis, and 1-triple
TTA had no effect on the hepatic fructose 6-phosphate level or the gene expression of Ogt. The
pentose phosphate pathway does not involve oxidation of glucose, and its primary role is ana-
bolic rather than catabolic. Interestingly, 1-triple TTA increased the gene expression of glucose
6-phosphate dehydrogenase accompanied by unchanged liver levels of NADPH. One of the
uses of NADPH in the cells is to prevent oxidative stress, and in addition the production of
ribose-5 phosphate by the pentose phosphate pathway is used in the synthesis of nucleotides
and nucleic acids. Noteworthy, fatty acid analogues containing a S-atom in the three-position
from the carboxyl end, i.e. tetradecylthioacetic acid (TTA), are reported to increase the redox
state and decrease inflammation [33–36]. Moreover, TTA and 1-triple TTA stimulate mito-
chondrial biosynthesis accompanied by an increased amount of mitochondrial DNA [2].
In conclusion, decreased gluconeogenesis, mediated by down-regulation of PEPCK–C and
pyruvate kinase accompanied by reduced pyruvate dehydrogenase activity, indicate plasma
and liver glucose-lowering potential with the mitochondrially targeted fatty acid analogue
1-triple TTA in rats. The regulation of the PDH activity level by increased gene expression of
pyruvate dehydrogenase kinase 4 was further supported by similar observations in human
liver cells treated with 1-triple-TTA. Upregulation of the pentose phosphate pathway seemed
to run in parallel with reduced glycolysis. Further studies are required to evaluate the potential
use of 1-triple TTA to target pathogenic mechanism in disorders such as insulin resistance and
type 2 diabetes in humans.
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